The cell-penetrating peptide, Pep-1, has activity against intracellular chlamydial growth but not extracellular forms of Chlamydia trachomatis

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 1, 2009, Pages 115-123

  Park, Narae ^a   Yamanaka, Kinrin ^a   Tran, Dat ^a   Chandrangsu, Pete ^a   Akers, Johnny C ^a   De Leon, Jessica C ^a   Morrissette, Naomi S ^b   Selsted, Michael E ^a   Tan, Ming ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antimicrobial activity; Antimicrobial agents; Antimicrobial peptides; Chlamydia spp.

Indexed keywords

CELL PENETRATING PEPTIDE; PEPTIDE PEP 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; CELL INCLUSION; CELL STRAIN L 929; CHLAMYDIA TRACHOMATIS; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG SYNTHESIS; ELECTRON MICROSCOPY; ESCHERICHIA COLI; GROWTH INHIBITION; MOUSE; NONHUMAN; SENSITIVITY AND SPECIFICITY; SPECIES DIFFERENCE; STAPHYLOCOCCUS AUREUS; TOXOPLASMA GONDII;

ANIMALS; ANTI-BACTERIAL AGENTS; CELLS, CULTURED; CHLAMYDIA TRACHOMATIS; COLONY COUNT, MICROBIAL; CYSTEAMINE; CYTOPLASM; ESCHERICHIA COLI; INCLUSION BODIES; MICE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, TRANSMISSION; PEPTIDES; STAPHYLOCOCCUS AUREUS; TOXOPLASMA;

EID: 57649207925     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn436     Document Type: Article

References (26)

1. Hughes G, Simms I, Leong G. Data from UK genitourinary medicine clinics, 2006: A mixed picture. Sex Transm Infect 2007; 83: 433-5.
2. CDC. Summary of Notifiable Diseases - United States, 2005. MMWR 2005; 54: 2-92.
3. Gambhir M, Basanez MG, Turner F et al. Trachoma: Transmission, infection, and control. Lancet Infect Dis 2007: 7: 420-7.
4. Kauppinen M, Saikku P. Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment. Clin Infect Dis 1995; 21: S244-52.
5. Belland RJ, Ouellette SP, Gieffers J et al. Chlamydia pneumoniae and athersclerosis. Cell Microbiol 2004; 6: 117-27.
6. Ballweber LM, Jaynes JE, Stamm WE et al. In vitro microbicidal activities of cecropin peptides D2A21 and D4E1 and gel formulations containing 0.1 to 2% D2A21 against Chlamydia trachomatis. Antimicrob Agents Chemother 2002; 46: 34-41.
7. Yasin B, Harwig SS, Lehrer RI et al. Susceptibility of Chlamydia trachomatis to protegrins and defensins. Infect Immun 1996; 64: 709-13.
8. Yasin B, Lehrer RI, Harwig SS et al. Protegrins: Structural requirements for inactivating elementary bodies of Chlamydia trachomatis. Infect Immun 1996; 64: 4863-6.
9. Yasin B, Pang M, Lehrer RI et al. Activity of Novispirin G-10, a novel antimicrobial peptide against Chlamydia trachomatis and vaginosis-associated bacteria. Exp Mol Pathol 2003; 74: 190-5.
10. Yasin B, Pang M, Wagar EA. A cumulative experience examining the effect of natural and synthetic antimicrobial peptides vs. Chlamydia trachomatis. J Pept Res 2004; 64: 65-71.
11. Chong-Cerrillo C, Selsted ME, Peterson EM et al. Susceptibility of human and murine Chlamydia trachomatis serovars to granulocyte- and epithelium-derived antimicrobial peptides. J Pept Res 2003; 61: 237-42.
12. Donati M, Di Francesco A, Gennaro R et al. Sensitivity of Chlamydia suis to cathelicidin peptides. Vet Microbiol 2007; 123: 269-73.
13. Donati M, Di Leo K, Benincasa M et al. Activity of cathelicidin peptides against Chlamydia spp. Antimicrob Agents Chemother 2005; 49: 1201-2.
14. Moulder JW. Interaction of chlamydiae and host cells in vitro. Microbiol Rev 1991; 55: 143-90.
15. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-95.
16. Morris MC, Depollier J, Mary J et al. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001; 19: 1173-6.
17. Zhu WL, Lan H, Park IS et al. Design and mechanism of action of a novel bacteria-selective antimicrobial peptide from the cell-penetrating peptide Pep-1. Biochem Biophys Res Commun 2006; 349: 769-74.
18. Peterson EM, Zhong GM, Carlson E et al. Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity. Infect Immun 1988; 56: 885-91.
19. Tang YQ, Yuan J, Osapay G et al. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated α-defensins. Science 1999; 286: 498-502.
20. Tran D, Tran PA, Tang YQ et al. Homodimeric χ-defensins from rhesus macaque leukocytes: Isolation, synthesis, antimicrobial activities, and bacterial binding properties of the cyclic pepticles. J Biol Chem 2002; 277: 3079-84.
21. van Abel RJ, Tang YQ, Rao VS et al. Synthesis and characterization of indolicidin, a tryptophan-rich antimicrobial peptide from bovine neutrophils. Int J Pept Protein Res 1995; 45: 401-9.
22. Dobrowolski JM, Sibley LD. Toxoplasma invasion of mammalian cells is powered by the actin cytoskeleton of the parasite. Cell 1996; 84: 933-9.
23. Hogan RJ, Mathews SA, Mukhopadhyay S et al. Chlamydial persistence: Beyond the biphasic paradigm. Infect Immun 2004; 72: 1843-55.
24. Tamura A, Matsumoto A, Higashi N. Purification and chemical composition of reticulate bodies of the meningopneumonitis organisms. J Bacteriol 1967; 93: 2003-8.
25. Lazarev VN, Parfenova TM, Gularyan SK et al. Induced expression of melittin, an antimicrobial peptide, inhibits infection by Chlamydia trachomatis and Mycoplasma hominis in a HeLa cell line. Int J Antimicrob Agents 2002; 19: 133-7.
26. Lazarev VN, Shkarupeta MM, Titova GA et al. Effect of induced expression of an antimicrobial peptide melittin on Chlamydia trachomatis and Mycoplasma hominis infections in vivo. Biochem Biophys Res Commun 2005; 338: 946-50.